<DOC>
	<DOCNO>NCT00242138</DOCNO>
	<brief_summary>The optimal duration hormonal therapy yet determine treatment locally advance carcinoma prostate . The RTOG perform trial 4 month neoadjuvant concurrent hormone ( consist Goserelin Flutamide ) compare radiation alone , find improvement local control progression-free survival , improvement overall survival . The EORTC perform similar trial , use Goserelin alone period 3 year . This trial show improvement local control , disease-free survival , contrast RTOG trial , improvement overall survival . The rate erectile dysfunction men receive prolonged period Gosereline ( i.e . 2 yr ) know , suspect accord expert opinion , significantly high short course hormonal ablation . Therefore price survival advantage locally advanced prostate cancer maybe cost increased rate erectile dysfunction .</brief_summary>
	<brief_title>Erectile Dysfunction/Prostate/RT/Androgen</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients clinical stage T1T4 carcinoma prostate Must undergone radical radiation least 2 year Pharmacological androgen ablation.Pharmacological androgen ablation may include : LHRHagonists without Nonsteroidal androgen ablation , Steroidal Antiandrogens , Progestational agent , Cypoterone ( Androcur ) . Must currently 6 month last injection LHRHagonists give every 3 month 4 month last injection , give monthly . If patient oral androgen ablation agent , must medication period least 4 month . currently hormonal therapy Able sign consent form fill questionnaire use study . No patient treat , currently treat Bicalutamide previous orchidectomy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>